Trial record 2 of 228 for:    Recruiting, Not yet recruiting, Available Studies | "Parasitic Diseases"

Compassionate Use of Triclabendazole for the Treatment of Parasites (Prior to FDA Approval; Expanded Access Program)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01931085
Expanded Access Status : Available
First Posted : August 29, 2013
Last Update Posted : January 31, 2018
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
Triclabendazole is a benzimidazole compound used as a systemic antihelmintic in veterinary practice. Triclabendazole is considered to be a second-line drug for parasites and is used when other preferred agents cannot be used because they are ineffective or because adverse reactions limit their use. Although Triclabendazole is widely used in developing countries for the treatment of parasites it is not approved by the FDA for this treatment in the US. It is currently being distributed in the US through a special arrangement with the FDA and the manufacturer on an individual patient approval basis. This arrangement requires that a single patient Investigational New Drug (IND) be obtained from FDA for each patient requiring Triclabendazole. Upon approval by FDA, the manufacturer (Novartis) will ship the drug directly to the prescribing physician.

Condition or disease Intervention/treatment
Parasitic Disease Drug: Triclabendazole

Study Type : Expanded Access
Official Title: "Compassionate Use of Triclabendazole for the Treatment of Parasites" (Prior to FDA Approval; Expanded Access Program)

Resource links provided by the National Library of Medicine

Intervention Details:
  • Drug: Triclabendazole
    Triclabendazole (10 mg/kg body-weight as a single dose).
    Other Name: Egaten

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Patients with a diagnosis of parasites whose resistance pattern has indicated resistance to first line agents and sensitivity to Triclabendazole or in whom an additional drug needs to be added to their regimen because of inadequate response to existing therapy.
  • Patients with a parasite that is sensitive to Triclabendazole and who have experienced an allergic or adverse reaction to other agents that prevent their use.
  • Patients with parasitic disease that has responded to treatment with first line drugs but who experienced allergic or adverse reactions to these agents that has prevented their continued use or who have experienced a relapse in their disease that necessitates the addition, or substitution, of second-line agents
  • Patients who do not qualify for a study using Triclabendazole or for whom a study does not exist and thus the patient would not otherwise have access to the drug

Exclusion Criteria:

  • Anyone whose parasitic disease can be adequately treated by other available medications.
  • Anyone who is allergic or who has had a severe adverse reaction to Triclabendazole in the past.
  • Pregnant Women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01931085

Contact: Marilyn Levi, MD 720-848-0817 MARILYN.LEVI@UCDENVER.EDU

Sponsors and Collaborators
University of Colorado, Denver
Principal Investigator: Marilyn Levi, MD University of Colorado, Denver

Responsible Party: University of Colorado, Denver Identifier: NCT01931085     History of Changes
Other Study ID Numbers: 11-1438
First Posted: August 29, 2013    Key Record Dates
Last Update Posted: January 31, 2018
Last Verified: January 2018

Additional relevant MeSH terms:
Parasitic Diseases
Antiparasitic Agents
Anti-Infective Agents